Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Zynex, Inc. (ZYXI)
March 14, 2025 4:25 PM EDT | Source: Scott+Scott Attorneys at Law LLP
New York, New York--(Newsfile Corp. - March 14, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION
Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals.
On March 11, 2025, after market hours, the Company released its 4Q24 and FY24 financial results, reporting only $45.98 million in revenue for the quarter, which represents a nearly 3% decline year-over-year. In a press release published the same day, the Company revealed TriCare, a payer representing 20-25% of the Company's annual revenue, has "temporarily suspended payments as they review prior claims." As a result, the Company also announced it was decreasing its overall staff by 15%. On this news, Zynex's stock price fell $3.59, or nearly 51%, to close at $3.41 per share on March 12, 2025, on heavy trading volume.
ARE YOU A POTENTIAL CLASS MEMBER ELIGIBLE TO RECOVER? CLICK HERE
If you have purchased Zynex securities, and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Nicholas Bruno at (888) 398-9312 or at nbruno@scott-scott.com.
CLICK HERE TO FIND OUT IF YOU CAN RECOVER YOUR LOSSES
About Scott+Scott
Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoing, including securities law and shareholder violations. With more than 100 attorneys in eight offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been repeatedly recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States.
This may be considered Attorney Advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244611
© 2025 Newsfile Corp. All rights reserved.
